Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

BACKGROUND: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. METHODS: In this phase 3, rand...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Baselga, José, Campone, Mario, Piccart, Martine, Burris, Howard A., Rugo, Hope S., Sahmoud, Tarek, Noguchi, Shinzaburo, Gnant, Michael, Pritchard, Kathleen I., Lebrun, Fabienne, Beck, J. Thaddeus, Ito, Yoshinori, Yardley, Denise, Deleu, Ines, Perez, Alejandra, Bachelot, Thomas, Vittori, Luc, Xu, Zhiying, Mukhopadhyay, Pabak, Lebwohl, David, Hortobagyi, Gabriel N.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705195/
https://ncbi.nlm.nih.gov/pubmed/22149876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1109653
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars